Qure.ai
Qure.ai is a Mumbai-born healthcare AI scale-up building radiology AI products for chest X-ray, CT brain, lung cancer, TB screening, and stroke triage. The organisation is strategically interesting because it combines three hard things: regulated AI product development, public-health deployment in low-resource markets, and US/EU clinical commercialisation.
Connected Notes
- Company Insights Hub
- Fractal - Qure.ai was incubated within Fractal Analytics.
- AI Native Organization - internal AI adoption opportunities and operating-system design.
- Operational Excellence - process maturity, OKRs, decision rights, and operating cadence.
- Hiring Systems - rare-talent acquisition for ML + medical imaging roles.
- Leadership - founder-led scaling, delegation, and CEO bandwidth.
- Growth Systems - GTM segmentation, pipeline hygiene, and expansion motion.
- Product Strategy - clinical workflow, regulatory gates, and product-roadmap translation.
- Agents, RAG, MCP - possible internal AI knowledge and regulatory systems.
Company Overview
Snapshot
| Attribute | Detail |
|---|---|
| Legal entity | Qure.AI Technologies Private Limited |
| Founded | 2016, Mumbai, India |
| Origin | Incubated within Fractal Analytics |
| Founders | Prashant Warier, Pooja Rao |
| Stage | Late scale-up / Series D |
| Funding | ~$123M across 9 rounds |
| FY2025 revenue | INR 190 Cr, roughly $22-23M |
| Team size | ~260 employees as of Mar 2025 |
| Deployment footprint | 3,000+ sites across 100+ countries |
| Regulatory position | 26 FDA clearances across 9 products; 65+ EU MDR CE marks |
| Recognition | TIME100 Most Influential Companies 2025; ET Startup Top Innovator Award 2025 |
| Key investors | Lightspeed, 360 One Asset, Merck, MassMutual, Novo Holdings, HealthQuad |
Mission
Make healthcare more accessible and equitable using deep learning and AI.
Operator translation: Qure.ai exists to put radiologist-grade diagnostic support into settings where human radiologists are absent, overloaded, or too expensive. The strongest public-health use cases are tuberculosis, lung cancer, brain trauma, and stroke.
Strategic Thesis
Qure.ai is not just a radiology AI vendor. At scale, it is a public-health infrastructure company plus a regulated clinical AI company. Its defensibility comes from the combination of:
- Proprietary medical imaging datasets.
- FDA and CE regulatory execution capability.
- Global deployment footprint in low- and middle-income countries.
- Clinical credibility through partnerships with WHO, AstraZeneca, NHS, Siemens Healthineers, and other institutions.
- Mission-driven employer brand for scarce AI talent.
Products
| Product | Modality | Use case |
|---|---|---|
| qXR | Chest X-ray | TB screening, lung nodule detection, 20+ chest conditions |
| qCT Brain | CT scan | Brain bleeds, midline shifts, stroke triage |
| qCT LN Quant | Chest CT | Lung nodule quantification and progression monitoring |
| qSpot-TB | Chest X-ray | AI-powered TB diagnosis; FDA Breakthrough Device designation in 2024 |
| qTrack | Multi-modality platform | Lung nodule management integrated with EMRs |
| qXR-Detect | Chest X-ray | FDA-cleared indications for ER physicians and radiologists |
| qCT Stroke | CT | Stroke detection and care coordination |
Revenue Model
| Stream | Description | Customers |
|---|---|---|
| SaaS / subscription | Per-seat or per-scan platform access | Hospitals, imaging centers, teleradiology companies |
| Government / public health contracts | Large TB and cancer screening deployments | Health ministries, WHO, public-health agencies |
| Enterprise partnerships | Co-deployment and research contracts | Pharma, NHS, OEM partners |
| Diagnostic network licensing | AI licensed to US/UK teleradiology networks | Teleradiology networks |
| Data / research partnerships | Anonymised aggregate data and clinical-trial evidence | Pharma and academic partners |
Operating Model
Value Creation Engine
- Medical images are generated at hospitals, clinics, screening camps, and diagnostic networks.
- Qure.ai models analyse X-rays and CTs in seconds.
- The system flags abnormalities, creates structured outputs, and integrates into clinical workflows.
- Clinicians and programme teams receive prioritised worklists, triage alerts, reports, dashboards, and tracking timelines.
- Customers get faster diagnosis, earlier detection, lower cost per read, and measurable programme outcomes.
Delivery Vectors
| Vector | Description | Operational dependency |
|---|---|---|
| SaaS platform delivery | Cloud API or on-prem deployment into hospitals and imaging sites | DevOps, MLOps, integration engineering, customer success |
| Government programme deployment | TB/cancer screening rollouts with field execution | Programme managers, field coordinators, government BD, regulatory |
| US/EU clinical channel | FDA-cleared products sold through hospitals and teleradiology networks | Regulatory, clinical validation, enterprise sales, CMO office |
Dual-Speed Organisation
Qure.ai likely operates with a fast product/engineering core and a slower commercial/regulatory deployment engine.
- Engineering cadence: weekly sprints, CI/CD, model iteration, deployment uptime.
- Commercial cadence: quarterly enterprise sales cycles, annual government contracts, public procurement, clinical validation.
- Coordination risk: engineering can outpace regulatory clearance and market readiness.
- Metrics tension: model accuracy and release velocity can conflict with contract value, renewal rate, and programme KPIs.
This is a direct Operational Excellence problem: the company needs an operating cadence that can connect fast technical iteration with slow regulated-market execution.
Organization Structure
Leadership Signals
Confirmed or publicly reported leadership roles in the report include:
- Prashant Warier - Co-Founder and CEO.
- Pooja Rao - Co-Founder / Head of R&D, with some uncertainty about current operating role.
- Preetham Putha - Chief AI Officer.
- Javier Zulueta - Chief Medical Officer, Pulmonology.
- Samir Shah - Chief Medical Officer.
- Bhargava Reddy - Chief Business Officer, Oncology.
- Surabhi Srivastava - Commercial Director.
Likely Functional Teams
| Team | Core purpose | Bottleneck risk |
|---|---|---|
| AI / Data Science | Build, validate, monitor, and improve imaging models | High: scarce talent, expensive annotation, regulatory validation lag |
| Product | Translate clinical need into FDA-clearable workflows | Medium-high: UX is complex across radiologists, ER physicians, and programme managers |
| Engineering / Platform | APIs, DICOM/HL7/FHIR, cloud, on-prem, security, CI/CD | Medium: integration complexity varies heavily by customer |
| Regulatory Affairs | FDA, CE, country approvals, clinical evidence, labelling | High: regulatory team gates product launch and revenue timing |
| Commercial / BD | Enterprise, government, pharma, OEM, US expansion | High: three GTM motions need very different skills |
| Customer Success / Deployment | Site activation, user training, integration, outcomes | Medium-high: 3,000+ sites in 100+ countries is hard to support manually |
| Clinical / Medical Affairs | Clinical validation, KOLs, publications, medical credibility | Medium: evidence timelines are long |
| HR / People Ops | Hire and retain ML, regulatory, clinical, and commercial talent | High: rare talent pool and likely underbuilt recruiting system |
Growth Strategy
Market Positioning
Qure.ai’s distinct position is the bridge between LMIC public health and regulated US/EU clinical AI. Most competitors are either emerging-market public-health players or premium US/EU clinical workflow vendors. Qure.ai is trying to be both.
Competitive Advantage
- Strongest chest/lung regulatory portfolio among radiology AI vendors in the report.
- 3,000+ deployments in 100+ countries.
- WHO and government programme relationships.
- Proprietary imaging dataset and clinical evidence base.
- Mission-led employer and customer narrative.
- Ability to generate real-world evidence from a large installed base.
Competitor Map
| Company | Position | Qure.ai contrast |
|---|---|---|
| Aidoc | US-focused radiology workflow AI | Broader workflow platform, but weaker LMIC/public-health position |
| Viz.ai | Stroke and care coordination AI | Stronger US hospital relationships, but less TB/lung public-health depth |
| Lunit | Chest X-ray, mammography, oncology | Strong AI imaging competitor, public-company pressure |
| Annalise.ai | Broad chest X-ray findings | Breadth play vs Qure.ai’s depth and deployment footprint |
AI Strategy
Current AI Usage
Externally, Qure.ai is AI-native at the product layer: deep learning for medical imaging, model validation, structured reporting, workflow triage, and deployment analytics.
Internally, the report argues that Qure.ai may underuse AI in its own operating systems. This creates a useful AI Native Organization case study: even AI product companies can have traditional internal workflows.
High-ROI Internal AI Opportunities
| Function | Opportunity | Why it matters |
|---|---|---|
| Customer Success | AI-powered site adoption monitoring | 3,000+ sites cannot be manually monitored for usage, adoption, and programme risk |
| Regulatory | RAG over FDA submissions and evidence | Regulatory Affairs is the product-launch gate; better drafting and evidence synthesis can save weeks/months |
| Knowledge Management | Internal AI copilot | Captures clinical, deployment, regulatory, and commercial knowledge before it stays trapped in people |
| Engineering | AI-assisted code review, test generation, model drift detection | Reduces manual review burden and protects deployed model quality |
| Commercial | Tender intelligence, call coaching, account health scoring | Improves qualified pipeline, win rate, and NRR |
| People Ops | AI-assisted JD writing, screening, personalised onboarding | Speeds time-to-shortlist and time-to-productivity |
Potential implementation patterns connect to RAG, Agents, and MCP:
- RAG system over FDA submissions, clinical evidence, SOPs, and post-market documentation.
- Agentic customer-success monitor that flags low usage and suggests interventions.
- Internal knowledge copilot connected to CRM, deployment notes, product docs, and regulatory playbooks.
Organizational Bottlenecks
| Bottleneck | Root cause | Impact | Severity | Fix |
|---|---|---|---|---|
| Regulatory clearance pipeline | FDA cycles are structurally long; submission quality and resourcing matter | New-product revenue delayed by 1-2 years | Critical | Dedicated regulatory project managers, submission templates, FDA pre-sub discipline |
| ML + medical imaging talent scarcity | Rare intersection of deep learning and radiology | Slower model development; quality compromise risk | Critical | Employer brand, university pipelines, internal upskilling |
| Three-vector commercial model | B2G, B2B enterprise, and US clinical require different motions | Sales dilution and unclear accountability | High | Dedicated GTM units with separate leaders and KPIs |
| Under-scaled Customer Success | Deployment footprint exceeds manual support model | Low adoption, renewal risk, weak programme outcomes | High | Tiered CS: high-touch enterprise, scaled digital programme support |
| Research/clinical/commercial silos | Model metrics do not automatically translate into customer workflow value | Products may optimise accuracy but miss adoption | High | Cross-functional clinical-product squads and formal field feedback loops |
| Dual-speed org friction | Engineering can move faster than commercial and regulatory gates | Feature backlog, frustration, misaligned promises | Medium | Quarterly product-commercial-regulatory prioritisation reviews |
| Founder-centralised decisions | CEO still likely involved in too many recurring decisions | Slower decisions, weak middle-management ownership | Medium | Tier 1/2/3 decision framework and documented authority matrix |
| Inconsistent onboarding | Knowledge lives in people and teams | Slow ramp, repeated mistakes, retention risk | Medium | 30/60/90 onboarding tracks and internal knowledge base |
Scaling Readiness
Overall readiness score from the report: 5.6/10.
| Dimension | Score | Readout |
|---|---|---|
| Process maturity | 5/10 | AI and regulatory processes are stronger than customer-facing processes |
| Documentation maturity | 4/10 | Technical documentation likely strong; operating documentation likely thin |
| Hiring readiness | 5/10 | Strong mission and values, but niche technical recruiting is hard |
| Leadership scalability | 6/10 | Strong founding team; needs COO/VP Ops to reduce CEO bandwidth load |
| System scalability | 6/10 | Cloud scalable; DICOM/on-prem integration complexity slows deployment |
| Data maturity | 8/10 | Proprietary imaging dataset is a real moat |
| Culture scalability | 6/10 | Mission helps retention; US/India split may dilute culture |
| Operational resilience | 5/10 | Key-person concentration and government-contract cyclicality create risk |
Interpretation: Qure.ai is ready to scale commercially only if its operating infrastructure catches up with product maturity.
Culture and Leadership
Culture Profile
- Mission-driven and founder-led.
- High analytical standards from technical founding DNA.
- Strong innovation culture in AI research and regulatory execution.
- Likely weaker operational rigour in internal process design.
- Cross-geography communication risk across India, US, UK, and programme markets.
- Mission is an underused talent and employer-brand asset.
Leadership Challenge
The CEO is likely still a major decision bottleneck. At ~260 people, the company needs a shift from founder-centred judgment to documented operating mechanisms.
Relevant Leadership questions:
- Which decisions must remain CEO-only?
- Which decisions should move to functional leaders?
- What recurring operating cadence gives visibility without centralising control?
- How does the company preserve mission and quality standards while reducing founder dependency?
Recommendations
High Impact
- Redesign commercial organisation into three dedicated GTM units: US Clinical, Global Enterprise, and Government Programmes.
- Hire a COO or VP Operations to build the internal operating system.
- Build a formal technical talent acquisition function for ML + medical imaging roles.
- Implement a tiered Customer Success model.
- Build an AI-powered internal knowledge system.
- Create a delegation framework and decision authority matrix.
- Deploy AI for regulatory document management and FDA submission preparation.
- Establish a clinical-commercial-product feedback loop.
- Design a structured 90-day onboarding programme.
- Implement OKRs across departments, starting with pilots.
Medium Impact
- Build people analytics.
- Create US-India operating rhythm and async communication protocols.
- Improve CRM discipline and revenue operations.
- Build technical career ladders.
- Deploy site adoption monitoring dashboards.
- Establish regulatory intelligence working group.
- Create research-to-product pipeline.
- Use publications and open-source selectively for employer brand.
Long Term
- Internal AI hackathons and experimentation time.
- Vendor-neutral partner ecosystem.
- Data governance board.
- AI ethics review process.
- Programme impact measurement framework.
- Quarterly culture surveys.
- IPO-readiness playbook.
90-Day Organisation Builder Plan
Days 1-30: Observation and Diagnosis
Objective: Build a credible map of how the organisation really works.
Actions:
- 1:1s with department heads.
- Shadow sales call, customer onboarding, and engineering standup.
- Review goals/OKRs, meeting cadences, decision forums, tools, attrition, and exit themes.
- Map decision rights and recurring bottlenecks.
Deliverables:
- Organisation diagnostic report.
- Current-state operating model.
- Decision authority audit.
- Stakeholder influence map.
- Tool and system inventory.
Days 31-60: System Design and Pilots
Objective: Design solutions for the top bottlenecks and prove value with low-risk pilots.
Actions:
- Draft decision authority matrix.
- Pilot OKRs in two departments.
- Design engineering onboarding track.
- Launch internal knowledge-base pilot.
- Workshop commercial redesign with CEO and commercial leaders.
- Run baseline culture survey.
Deliverables:
- Tier 1/2/3 decision model.
- Pilot OKR set.
- Engineering onboarding playbook v1.
- Knowledge base with top 50 institutional documents.
- Commercial org redesign proposal.
- Baseline culture survey results.
Days 61-90: Rollout and Optimisation
Objective: Roll out approved initiatives without overwhelming the organisation.
Actions:
- Launch company-wide OKR cycle if approved.
- Implement CS tiering and assign top enterprise accounts.
- Roll out onboarding programme to next new-hire cohort.
- Present commercial redesign to board.
- Create six-month transformation roadmap.
Key risks:
- OKRs perceived as surveillance.
- Commercial redesign creates internal politics.
- CEO sponsorship is weak or inconsistent.
- Too many changes create fatigue.
Mitigation:
- CEO publicly sponsors changes in all-hands.
- Commercial redesign is co-designed with current leaders.
- Limit simultaneous org-wide changes to three.
- Show measurable early wins.
Lessons for CookieYes
- Regulatory capability can be a moat, not just a compliance cost. For CookieYes, privacy regulation can be treated as product and operating advantage.
- Customer Success must scale before deployment count becomes vanity. Track active usage, health, and value delivered, not just customer logos.
- Build knowledge systems early. Compliance, product, customer, and sales learnings should not live only in people.
- Segment GTM by buyer and motion. Different buyer types need different sales skills, enablement, KPIs, and renewal paths.
- Mission can improve hiring yield when converted into a concrete employer-brand system.
Lessons for Mozilor
- Product-market expansion creates operational complexity before it creates durable revenue. Separate GTM units when motions differ meaningfully.
- Strong technical capability is not enough; adoption depends on onboarding, workflow integration, customer education, and success analytics.
- Founder-led quality needs to become system-led quality through decision matrices, playbooks, and operating reviews.
- Internal AI should start where operational leverage is highest: knowledge management, customer health, support triage, and sales intelligence.
Lessons for Organization Building
- The company is a strong example of product capability outpacing organisational infrastructure.
- The most important organisation-building role is to build the operating system around exceptional talent.
- Scale-up risk is often not product risk; it is decision speed, GTM clarity, onboarding, knowledge transfer, and leadership bandwidth.
- A dual-speed organisation needs explicit translation layers between fast engineering and slow market/regulatory systems.
- AI-native product companies still need deliberate internal AI adoption.
Strategic Ideas Inspired
- Build an internal knowledge copilot for organisation-building notes using RAG over company research, leadership notes, hiring systems, and operating playbooks.
- Create a company-research template that always captures: business model, operating model, org structure, bottlenecks, AI opportunities, 90-day plan, and lessons for CookieYes/Mozilor.
- Design a
deployment-to-adoptiondashboard pattern for any SaaS business: deployed, active, high-utilisation, at-risk, expansion-ready. - Create a decision-rights template for founder-led scale-ups: Tier 1 CEO-only, Tier 2 leadership team, Tier 3 functional owners.
- Build a 30/60/90 onboarding template for technical and commercial hires.
Mozilor / CookieYes Task Reflection
- Task title: Qure.ai research note
- Objective of the task: Understand Qure.ai’s operating model and extract lessons that can improve Mozilor’s product, research, governance, and execution quality, especially for CookieYes.
- Date assigned and date submitted: Assigned during the Mozilor organization-building research cycle; submitted on 2026-06-26.
- Your submission / output: This research note, plus the supporting takeaways and operating ideas for Mozilor and CookieYes.
- Key learning or insight gained: Regulated products need clear decision rights, workflow fit, and discipline around trust.
- How the task connects to organizational thinking, execution, research, or role readiness: It trains me to convert external company research into operating principles that help Mozilor and CookieYes scale with clarity, trust, and repeatable execution.